324 related articles for article (PubMed ID: 12187959)
41. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
[TBL] [Abstract][Full Text] [Related]
42. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
43. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
[TBL] [Abstract][Full Text] [Related]
44. Spinal cord ependymomas and myxopapillary ependymomas in the first 2 decades of life: a clinicopathological and immunohistochemical characterization of 19 cases.
Stephen JH; Sievert AJ; Madsen PJ; Judkins AR; Resnick AC; Storm PB; Rushing EJ; Santi M
J Neurosurg Pediatr; 2012 Jun; 9(6):646-53. PubMed ID: 22656257
[TBL] [Abstract][Full Text] [Related]
45. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
[TBL] [Abstract][Full Text] [Related]
46. The clinical and prognostic relevance of grading in intracranial ependymomas.
Ernestus RI; Schröder R; Stützer H; Klug N
Br J Neurosurg; 1997 Oct; 11(5):421-8. PubMed ID: 9474274
[TBL] [Abstract][Full Text] [Related]
47. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
48. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
49. Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival.
Wostrack M; Ringel F; Eicker SO; Jägersberg M; Schaller K; Kerschbaumer J; Thomé C; Shiban E; Stoffel M; Friedrich B; Kehl V; Vajkoczy P; Meyer B; Onken J
J Neurosurg Spine; 2018 Jun; 28(6):654-662. PubMed ID: 29521579
[TBL] [Abstract][Full Text] [Related]
50. Clear cells are associated with proliferative activity in ependymoma: a quantitative study.
Ishizawa K; Komori T; Aihara Y; Maruyama T; Okada Y; Ikuta S; Muragaki Y; Hirose T; Homma T; Sasaki A
Clin Neuropathol; 2012; 31(3):146-51. PubMed ID: 22551919
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.
Yan X; Cheng X; Liu J; Luo D; He X; Chen F; Qin C; Wang Y
Clin Invest Med; 2008; 31(4):E206-11. PubMed ID: 18682044
[TBL] [Abstract][Full Text] [Related]
52. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
[TBL] [Abstract][Full Text] [Related]
53. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling.
Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL
Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636
[TBL] [Abstract][Full Text] [Related]
54. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
56. Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases.
Virág J; Haberler C; Baksa G; Piurkó V; Hegedüs Z; Reiniger L; Bálint K; Chocholous M; Kiss A; Lotz G; Glasz T; Schaff Z; Garami M; Hegedűs B
Pathol Oncol Res; 2017 Apr; 23(2):245-252. PubMed ID: 27395057
[TBL] [Abstract][Full Text] [Related]
57. p53 Pathway dysfunction in primary childhood ependymomas.
Gaspar N; Grill J; Geoerger B; Lellouch-Tubiana A; Michalowski MB; Vassal G
Pediatr Blood Cancer; 2006 May; 46(5):604-13. PubMed ID: 16086408
[TBL] [Abstract][Full Text] [Related]
58. Antineuronal nuclei immunohistochemical staining patterns in childhood ependymomas.
Parker JR; Armstrong DL; Strother D; Rudman DM; Dauser RC; Laurent JP; Deyd J; Rouah PE
J Child Neurol; 2001 Aug; 16(8):548-52. PubMed ID: 11510923
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical markers for prognosis of cerebral glioblastomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
[TBL] [Abstract][Full Text] [Related]
60. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
